Bolt Biotherapeutics Announces Board and Executive Changes
Ticker: BOLT · Form: 8-K · Filed: Dec 23, 2024 · CIK: 1641281
| Field | Detail |
|---|---|
| Company | Bolt Biotherapeutics, Inc. (BOLT) |
| Form Type | 8-K |
| Filed Date | Dec 23, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, executive-compensation, board-of-directors
TL;DR
Bolt Bio just filed an 8-K about board and exec comp changes. Watch this space.
AI Summary
On December 23, 2024, Bolt Biotherapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates a shift in leadership and potential adjustments to how key personnel are compensated.
Why It Matters
Changes in a company's board and executive compensation can signal strategic shifts or internal restructuring that may impact future performance and investor confidence.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can indicate underlying issues or strategic pivots that may affect the company's future performance.
Key Numbers
- 001-39988 — Commission File Number (Identifies the company's SEC filing history.)
- 47-2804636 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Bolt Biotherapeutics, Inc. (company) — Registrant
- December 23, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 900 Chesapeake Drive, Redwood City, California 94063 (address) — Principal Executive Offices
- (650) 665-9295 (phone_number) — Registrant's Telephone Number
FAQ
What specific changes were made to the board of directors?
The filing indicates changes related to the 'Departure of Directors or Certain Officers' and 'Election of Directors', but the specific names and details of these changes are not provided in the excerpt.
What are the details of the executive compensation arrangements mentioned?
The filing notes 'Compensatory Arrangements of Certain Officers' as an item, but the specific details of these arrangements are not elaborated upon in the provided text.
When was this report filed with the SEC?
This report was filed on December 23, 2024.
What is Bolt Biotherapeutics, Inc.'s principal executive office address?
The principal executive offices are located at 900 Chesapeake Drive, Redwood City, California 94063.
What is the company's former name?
The company's former name was Bolt Therapeutics, Inc., with a date of name change on May 4, 2015.
Filing Stats: 484 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-12-23 16:10:06
Key Financial Figures
- $0.00001 — ch registered Common Stock, par value $0.00001 per share BOLT The Nasdaq Global Se
Filing Documents
- bolt-20241223.htm (8-K) — 36KB
- 0000950170-24-139580.txt ( ) — 151KB
- bolt-20241223.xsd (EX-101.SCH) — 25KB
- bolt-20241223_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Bolt Biotherapeutics, Inc. Date: December 23, 2024 By: /s/ William P. Quinn William P. Quinn President, Chief Executive Officer and Chief Financial Officer